SEC Comment Letter for Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248) (CMMB) — Apr 7, 2020
Chemomab Therapeutics Ltd. (CMMB) (CIK 0001534248)
Date: April 7, 2020 · CIK: 0001534248 · Accession: 0000000000-20-002988
AI Filing Summary & Sentiment
File numbers found in text: 001-38807
Letter
April 6, 2020 Frank Haluska Chief Executive Officer Anchiano Therapeutics Ltd. 5 Kiryat Hamada St. P.O. Box 45032 Jerusalem, 9777401, Israel Re:Anchiano Therapeutics Ltd. Preliminary Proxy Statement on Schedule 14A Filed March 30, 2020 File No. 001-38807 Dear Dr. Haluska: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Anna T. Pinedo
Show Raw Text
April 6, 2020
Frank Haluska
Chief Executive Officer
Anchiano Therapeutics Ltd.
5 Kiryat Hamada St.
P.O. Box 45032
Jerusalem, 9777401, Israel
Re:Anchiano Therapeutics Ltd.
Preliminary Proxy Statement on Schedule 14A
Filed March 30, 2020
File No. 001-38807
Dear Dr. Haluska:
We have completed our review of your filing. We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Anna T. Pinedo